Physician profile
Jonathan Pennington
NPI 1528689239
$1,909.20
in general payments reported to CMS, 2019-2025
22 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $239 · 2024: $530 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $683.57 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $222.75 | 2023-2025 | |
| Abbvie INC. | $178.25 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.36 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $134.07 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $89.76 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $68.03 | 2023-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $65.54 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $52.68 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.74 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $30.34 | 2024 | |
| Glaxosmithkline, LLC. | $27.58 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Scilex Pharmaceuticals INC. | $19.95 | 2025 | |
| Acadia Pharmaceuticals INC | $18.70 | 2025 | Daybue |
| Sumitomo Pharma America, INC. | $17.31 | 2025 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.99 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.97 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $15.65 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Axsome Therapeutics, INC. | $15.38 | 2023 | Auvelity |
| Genentech USA, INC. | $14.89 | 2023 | Phesgo, Alecensa, Tecentriq |
| Almatica Pharma LLC | $14.66 | 2023 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $13.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.